{"id":"W2955724587","doi":"10.1136/annrheumdis-2019-eular.496","title":"SAT0605 BODY MASS INDEX AND SYSTEMIC CORTICOSTEROID USE AS INDICATORS OF DISEASE BURDEN AND THEIR INFLUENCE ON THE SAFETY PROFILE OF CERTOLIZUMAB PEGOL ACROSS INDICATIONS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sanofi Genzyme; Genentech; Medac; Gilead Sciences; Servier; Celltrion; Regeneron Pharmaceuticals; Mylan; Amgen; Atlantic Healthcare; Eli Lilly and Company; Purdue Pharma; Dermira; UCB Pharma; Valeant Pharmaceuticals International; Pfizer; Biogen; Celgene; Nordic Pharma Group; Purdue University; Sanofi; Tillotts Pharma; Allergan; Seres Therapeutics; Galderma; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Certolizumab pegol; Psoriatic arthritis; Internal medicine; Psoriasis; Adverse effect; Body mass index; Rheumatoid arthritis; Comorbidity; Etanercept; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002205391,0.0003851259,0.0008400484,0.0005205602,0.0002426251,0.001329022,0.00038962,0.0005150386,0.002995732],"category_scores_gemma":[0.005590927,0.0001579882,0.001581762,0.001209574,0.0003294327,0.0005862913,0.0005044292,0.001351609,0.000557567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004165773,"about_ca_system_score_gemma":0.0006156611,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001199155,"about_ca_topic_score_gemma":0.001155375,"domain_scores_codex":[0.9985759,0.0005116533,0.000205331,0.0002282974,0.0003358213,0.0001429856],"domain_scores_gemma":[0.9929946,0.003236195,0.002306511,0.0004250137,0.000485093,0.0005525207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0448641,0.0002518535,0.9162893,0.0002570865,0.002998962,0.0001474277,0.0000900921,0.001015646,0.002774967,0.0003537736,0.001253361,0.0297034],"study_design_scores_gemma":[0.0002845962,0.002005254,0.9929897,0.00003536796,0.0007864814,0.0002601177,0.00006908971,0.001432264,0.000501861,0.0001941389,0.001422728,0.00001837491],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863366,0.005547596,0.0004959543,0.0002737162,0.00009720982,0.00003046025,0.003391952,0.00003300903,0.003793422],"genre_scores_gemma":[0.9961426,0.0004602243,0.0002577713,0.0001604353,0.00006675931,0.00001999975,0.002357072,0.00001406002,0.0005212312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002995732,"threshold_uncertainty_score":0.01166332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02289928183556837,"score_gpt":0.3096321335340153,"score_spread":0.2867328516984469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}